Indications for and implications of germline genetic testing (GGT) in patients with prostate cancer have expanded over the past decade, particularly related to precision therapies and management. GGT has become the standard of care for many cancers such as breast, ovarian, colorectal, pancreatic, and metastatic prostate cancer, and it is imperative that patients be offered timely and equitable access to testing as it can inform patient-physician shared decision making for management of the current cancer as well as anticipatory guidance for disease progression. Additionally, GGT guides screening for and prevention of secondary malignancies for the patient and cascade testing for at-risk family members. Here, we present data supporting the notion that clinicians should offer all patients with prostate cancer the opportunity to undergo comprehensive GGT for pathogenic germline variants known to be associated with familial cancer and/or known to have implications for treatment and management.
JCO oncology practice. 2024 Dec 19 [Epub ahead of print]
Neal Shore, Sarah M Nielsen, Edward D Esplin, Emmanuel S Antonarakis, Pedro C Barata, Tomasz M Beer, Himisha Beltran, Alan Bryce, Michael S Cookson, E David Crawford, Tanya B Dorff, Daniel J George, Elisabeth I Heath, Brian T Helfand, Maha Hussain, Rana R Mckay, Alicia K Morgans, Michael J Morris, Channing J Paller, Ashley E Ross, Oliver Sartor, John Shen, Paul Sieber, Matthew R Smith, David R Wise, Andrew J Armstrong
Carolina Urologic Research Center, Myrtle Beach, SC., Labcorp Genetics Inc (formerly Invitae Corp), San Francisco, CA., University of Minnesota, Masonic Cancer Center, Minneapolis, MN., Case Western Reserve University, Cleveland, OH., The Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Dana Faber Cancer Institute, Boston, MA., City of Hope Cancer Center, Goodyear, AZ., Stephenson Cancer Center, OU Health, The University of Oklahoma, Oklahoma City, OK., University California, San Diego, La Jolla, CA., Duke Cancer Institute, Duke University, Durham, NC., Karmanos Cancer Institute, Detroit, MI., NorthShore University HealthSystem/Endeavor Health, Evanston, IL., Northwestern Feinberg School of Medicine, Chicago, IL., Memorial Sloan Kettering Cancer Center, New York, NY., The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD., Mayo Clinic, Rochester, MN., UCLA David Geffen School of Medicine, Los Angeles, CA., Keystone Urology Specialists, Lancaster, PA., Massachusetts General Hospital, Boston, MA., Perlmutter Cancer Center, NYU Langone Health, New York, NY.